[68Ga]NOTA-Galactosyl Human Serum Albumin: a Tracer for Liver Function Imaging with Improved Stability by Roland Haubner et al.
Mol Imaging Biol (2017)
DOI: 10.1007/s11307-017-1046-1
* The Author(s), 2017. This article is published with open access at Springerlink.com
RESEARCH ARTICLE
[68Ga]NOTA-Galactosyl Human Serum Albumin:
a Tracer for Liver Function Imaging
with Improved Stability
Roland Haubner ,1 Andreas M. Schmid,2 Andreas Maurer,2 Christine Rangger,1
Llanos Geraldo Roig,1 Bernd J. Pichler,2 Irene J. Virgolini1
1Department of Nuclear Medicine, Medical University of Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria
2Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen,
Röntgenweg 13, 72076, Tübingen, Germany
Abstract
Purpose: Non-invasive techniques allowing quantitative determination of the functional liver
mass are of great interest for patient management in a variety of clinical settings. Recently, we
presented [68Ga]DTPA-GSA to target the hepatic asialoglycoprotein receptor for this purpose.
Here, we introduce [68Ga]NOTA-GSA to improve metabolic stability of the radiopharmaceutical
and compare the imaging properties with [68Ga]DTPA-GSA.
Procedures: Labeling of the compounds was carried out at room temperature using 1.9 M
sodium acetate as buffer. For quality control, thin-layer, high-performance liquid, and size
exclusion chromatographies were used. Metabolic stability was studied in rat and human
serums. For in vivo evaluation, Fischer rats were scanned by positron emission tomography and
magnetic resonance imaging and subsequently sacrificed for biodistribution studies. Time
activity curves (TACs) for heart and liver were generated and corresponding parameters (T50,
T90, LHL15, HH15) were calculated.
Results: [68Ga]NOTA-GSA can be produced in high radiochemical yield and purity (995 %)
within 15 min. Stability studies revealed almost no metabolite formation over the 2-h observation
period. Analysis of the TACs showed comparable results for most of the investigated
parameters. The only significant difference was found in the T90 value, where [
68Ga]NOTA-
GSA showed slower uptake in comparison with 68Ga-DTPA-GSA (123 ± 10 vs. 89 ± 3 s,
p G 0.01).
Conclusions: [68Ga]NOTA-GSA showed a significant increase of the metabolic stability and in
most organs lower background activity. However, comparison of LHL15 and HH15 indicates that
the increased stability did not further improve the diagnostic value. Thus, [68Ga]NOTA-GSA and
[68Ga]DTPA-GSA can be used equivalent for imaging hepatic function with positron emission
tomography.
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Introduction
During the last decade, an increasing interest in the use of
gallium-68 with positron emission tomography (PET) has
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been observed. This is mainly based not only on the
improving availability of corresponding Ge-68/Ga-68 gen-
erators [1] but also due to the very convincing results
obtained with Ga-68-labeled radiopharmaceuticals like
[68Ga]DOTATOC (see, e.g., [2]) and [68Ga]HBED-PSMA
(see, e.g., [3]). Thus, gallium-68 became an interesting
alternative to fluorine-18 in labeling compounds for imaging
with PET.
On the other hand, non-invasive methods allowing
quantitative determination of the functional liver mass are
of great interest for patient management in a diversity of
clinical settings comprising liver surgery and liver trans-
plantation [4–6] as well as diagnosis [7, 8] and therapy
monitoring [9] of cancer. Additionally, it has been revealed
that the evaluation of remnant liver function can help to
discriminate different stages of alcoholic liver cirrhosis [10]
and could be used to differentiate areas of steatosis, fibrosis,
and cholestasis [11]. Moreover, control of liver status before
and during peptide receptor radionuclide therapy (PRRT)
[12] could lead to an optimized patient management.
Furthermore, patients who are potentially suitable for
selective internal radiation therapy (SIRT) [13] may also
benefit from such a diagnostic method, allowing stratifying
patients according to their peri-interventional risk.
[99mTc]diethylenetriamine-pentaacetic acid galactosyl hu-
man serum albumin ([99mTc]GSA) [14] binds to the
asialoglycoprotein receptor (ASGP-R), a hepatic cell surface
receptor specific for galactose terminated glycoproteins [4].
This receptor is exclusively expressed on the sinusoidal surface
of mammalian hepatocytes. It has been proven that [99mTc]GSA
and dynamic single-photon emission computed tomography
(SPECT) allows estimation of regional hepatic function based
on the determination of the ASGP-R density [15, 16].
To combine the superior performance of PET compared
with SPECT concerning imaging resolution and quantifying
properties with the good properties of GSA in ASGP-R
targeting, we developed a Ga-68-labeled analog [17].
[68Ga]DTPA-GSA showed comparable targeting properties
as found for [99mTc]GSA but lack of high metabolic
stability. Thus, in this study, we introduce with 2-S-(4-
isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-
triacetic acid (p-NCS-Bn-NOTA) an alternative chelating
moiety and present stability data as well as the PET imaging
properties of [68Ga]NOTA-GSA and compare them with
[68Ga]DTPA-GSA.
Material and Methods
All reagents were obtained from VWR International GmbH
(Vienna, Austria) or Sigma-Aldrich Handels GmbH (Vi-
enna, Austria) and were used without further purification.
DTPA-conjugated galactosyl human serum albumin (GSA)
was a kind gift from Nihon Medi-Physics (Tokyo, Japan)
and was supplied as a freeze-dried technetium kit formula-
tion. The kit was reconstituted with water and directly used
for 68Ga labeling without isolation of the glycoprotein. The
mean number of DTPA groups per human serum albumin
(HSA) is 6 and the mean number of galactosyl units is 35
resulting in an estimated MW of 80,730 g/mol (for details,
see [17]). NOTA-GSA was supplied from piCHEM (Graz,
Austria) and includes six NOTA, conjugated via isothiocy-
anate chemistry and 19 galactosyl moieties per HSA
molecule resulting in an estimated MW of 76,398 g/mol.
The Ge-68/Ga-68 generator was purchased from Eckert &
Ziegler (Berlin, Germany) with a nominal activity of
1100 MBq and was eluted with 0.1 N HCl (Biochemical
grade, FLUKA, Switzerland).
Labeling of DTPA-GSA and NOTA-GSA
with Ga-68
For both compounds, Ga-68 labeling was carried out using a
fractionated elution protocol [18]. Synthesis of [68Ga]DTPA-
GSA followed the protocols published in [17]. Briefly,
100 μg DTPA-GSA (dissolved with water to 1 mg/ml using
the freeze-dried kit formulation) and 30 μl 1.9 M sodium
acetate solution was incubated for 30 min with 300 μl
[68Ga]GaCl3 in 0.1 M HCl (50–100 MBq) at room
temperature. In analogy, for labeling of NOTA-GSA
100 μg precursor (dissolved with water to 4 mg/ml) and
30 μl 1.9 M sodium acetate solution were incubated for
15 min with 300 μl [68Ga]GaCl3 in 0.1 M HCl (approx.
50 MBq) at room temperature.
For PET imaging studies, the ratio between precursor
amount and Ga-68 activity used was kept constant (1 μg per
MBq). Reaction was carried out at room temperature in
172 mM sodium acetate buffer for 30 min. This results in
specific activities of approx. 83 MBq/nmol for [68Ga]DTPA-
GSA and approx. 77 MBq/nmol for [68Ga]NOTA-GSA in
the animal studies.
For standard quality control, thin-layer chromatography
(TLC) and high-performance liquid chromatography
(HPLC) was used. TLC was carried out using Varian
iTLC-SG (Palo Alto, CA, USA) and 0.1 M sodium citrate
pH 5. For analysis of the TLC strips, a phosphor imager was
used (Cyclone Plus Storage Phosphor System, PerkinElmer,
Waltham, MA, USA). For HPLC a Dionex Ultimate 3000
RS HPLC system with pump, column compartment, and
variable wavelength UV detector (Thermofischer Scientific,
Vienna, Austria) and a Gabi Star radiometric detector
(Raytest, Straubenhardt, Germany) were used. A Vydac
218TP5215 C18 polymeric reversed phase column (5 μm,
300 Å, and 150 × 3.0 mm; SRD, Vienna, Austria), flow rates
of 1 ml/min, and UV detection at 220 nm were employed
with the following acetonitrile (ACN)/H2O/0.1 % trifluoro
acetic acid (TFA) gradient: 0–2 min 10 % ACN, 2–20 min
10–60 % ACN, 20–21 min 60–100 % ACN, and 21–26 min
100 % ACN.
Additionally, size exclusion chromatography (SEC) was
carried out to control for potential colloid formation.
Therefore, Sephadex G-25 PD-10 columns (GE Healthcare
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Europe GmbH, Vienna, Austria) were incubated with 15 ml
bovine serum albumin solution (BSA, 1 % in isotonic saline),
loaded with 0.2 ml reaction mixture, and washed with 7 ml
isotonic saline. Eluate and column were measured in a dose
calibrator.
Stability of [68Ga]DTPA-GSA and [68Ga]NOTA-
GSA
The metabolic stability in human serum was determined
after 2, 30, 60, and 120 min incubation of [68Ga]NOTA-
GSA at 37 °C. Hundred microliter [68Ga]NOTA-GSA
labeling solution per 1 ml serum were used for incubation.
For HPLC analysis, 400 μl samples of the human serum
were passed through a 0.20 μm sterile filter (Millex LG,
EMD Millipore, Bellerica, MA; activity remaining on the
sterile filter was between 1 and 2 %) and 20 μl aliquots were
injected to the HPLC (gradient A). Stability assay for
[68Ga]DTPA-GSA (gradient B) in human serum was carried
out following the same protocol and is described in [17].
Assays were carried out in duplicate.
The metabolic stability of [68Ga]NOTA-GSA and
[68Ga]DTPA-GSA in rat serum was determined after 2, 30,
and 60 min at 37 °C. Therefore, 20 μl of the corresponding
tracer was added to 200 μl of serum. At the corresponding
time points, 20 μl aliquots were removed and diluted with
80 μl water, passed through a 0.20 μm sterile filter, and the
filter was washed with 100 ml water. Eighty microliter
samples were analyzed using HPLC and gradient A. Assays
were carried out in duplicate.
ACN/H2O/0.1 % TFA gradients were 0–2 min 10 %
ACN, 2–20 min 10–60 % ACN, 20–21 min 60–100 %
ACN, and 21–26 min 100 % ACN (gradient A) and 0–2 min
0 % ACN, 2–18 min 0–80 % ACN, 18–19 min 80–100 %
ACN, and 19–23 min 100 % ACN (gradient B).
Imaging and Biodistribution Studies
For the in vivo comparison of [68Ga]NOTA-GSA and
[68Ga]DTPA-GSA, two groups of healthy male Fischer
rats (n = 4 per group, 253 ± 11 g) were measured in a
sequential PET/MRI setup. Animals were anesthetized in
1.5 % isoflurane evaporated in medical oxygen and placed
on the PET Scanner (Inveon dedicated PET, Siemens
Healthcare, Knoxville, TN, USA). After injection of the
corresponding tracer (4.9 ± 0.1 MBq of [68Ga]NOTA-
GSA and 5.1 ± 0.1 MBq of [68Ga]DTPA-GSA) animals
were measured dynamically for 30 min followed by a
transmission scan for attenuation correction. PET data
were reconstructed using OSEM2D reconstruction algo-
rithm including the attenuation correction. For an ana-
tomical scan (3D RARE, TR/TE = 300/29 ms) the
animals were transferred on the animal bed without
moving the animal to a 7T MRI (BioSpec, Bruker Biospin
GmbH, Ettlingen, Germany).
For biodistribution studies, blood samples were taken and
animals were sacrificed immediately after imaging studies
were finished. Organs (liver, lung, kidneys, spleen, heart,
gut, stomach, and brain) as well as muscle were excised. The
samples were weighed and activity in the samples was
measured using a γ-counter (Wizard single-detector-counter;
PerkinElmer, Waltham, MA, USA). Results are expressed as
the percentage injected dose per gram of tissue (%ID/g).
Each value represents the mean and SD of four animals. All
animal experiments were approved by the German compe-
tent authorities (Regierungspräsidium Tübingen; R12/13).
Fig. 1. Schematic structure of a [68Ga]DTPA-GSA and b [68Ga]NOTA-GSA. Differences are found in the chelator type and the
amount of sugar conjugated to the human serum albumin (HSA).
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For analysis, the images of PET and MRI were fused and
regions of interest were drawn on the basis of the MRI,
covering the entire liver and the left ventricle for the cardiac
input curve using Inveon Research Workplace (IRW,
Siemens Healthcare). Time activity curves (TACs) were
analyzed and characterizing parameters were calculated
using MatLab (Mathworks, Natick, MA, USA). Briefly, a
second-degree polynomial was fitted into the five points
around the maximal value of the cardiac input function,
defining t0 for the experiment. Subsequently, a decreasing
exponential function y = A ⋅ exp (−b ⋅ x) + c was fitted into
the cardiac TAC, starting at the peak value of the
polynomial. Liver uptake was also characterized by an
exponential function, but was fitted over the entire dataset.
Based on these functions, characteristic parameters for blood
clearance (T50 = time to reach 50 % of the maximum heart
uptake; HH15 = blood activity at 15 min divided by the
blood activity at 3 min; decaying constant b of the fit) and
functional liver reserve (T90 = time to reach 90 % of the
maximum liver uptake; LHL15 = liver activity at 15 min
Fig. 2. a Comparison of the metabolic stability of [68Ga]NOTA-GSA (blue) and [68Ga]DTPA-GSA (red) in human serum after 30-
, 60-, and 120-min incubation at 37 °C (for [68Ga]NOTA-GSA additional samples were taken approx. 2 min after start of
incubation) and comparison of the stability in rat serum ([68Ga]NOTA-GSA (light blue), [68Ga]DTPA-GSA (orange)) after 2-, 30-,
and 60-min incubation at 37 °C. Studies were carried out in duplicate (for [68Ga]NOTA-GSA standard deviation is very low and
cannot be visualized due to the size of the used symbols). b HPLC diagrams of the different compounds after 120-min
incubation in human serum. The retention times of the intact tracers are 16.6 min (gradient A) and 12.3 min (gradient B) for
[68Ga]NOTA-GSA and [68Ga]DTPA-GSA, respectively.
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Labeling of NOTA-GSA (for proposed structure, see Fig. 1)
with gallium-68 could be carried out in radiochemical yield
and purity 995 % determined by HPLC as well as TLC.
Additional analysis of potential colloid formation using SEC
demonstrated that the formulation contains 997 %
[68Ga]NOTA-GSA and indicating that if at all only low
amounts of colloid had been formed. The specific activities
of the studied preparations were in the range of 38–77 MBq
per nmol NOTA-GSA. Due to the fact that no separation of
the unlabelled compound is possible, the specific activity
strongly depends on the amount of precursor used.
Stability Assays
Incubation of [68Ga]NOTA-GSA with human serum up to
120 min demonstrated high metabolic stability of the tracer
(Fig. 2). Over the whole observation period of 120 min,
more than 98 % intact tracer was found if samples were
analyzed via HPLC. In contrast, rapid degradation was
found for 68Ga-DTPA-GSA. Already after 30-min incuba-
tion, only approx. 70 % intact tracer was found. After 120 min,
the amount of intact tracer was further reduced to 30 %. Due to
the low retention time, it can be assumed that the observed
Bdegradation product^ is mainly due to release of the
radiometal from the chelating system.
The same behavior is found when analyzing the meta-
bolic stability in rat serum. Again, [68Ga]NOTA-GSA was
stable over the observation period of 60 min (imaging data
where recorded not longer than 30 min; thus for the rat
study, observation time was reduced) whereas a significant
reduction of intact [68Ga]DTPA-GSA was observed. After 1-
Fig. 3. Comparison of [68Ga]NOTA-GSA and [68Ga]DTPA-GSA accumulation in vivo. In representative images a both
compounds yielded comparable results 30 min post injection. High uptake in the liver is found while in all other organ activity
concentration was negligible. At first glance time activity curves (b, c) were comparable. However, [68Ga]DTPA-GSA reached a
slightly higher uptake followed by a wash-out in the liver (b) and higher background activity in the blood pool (c) compared to
[68Ga]NOTA-GSA.
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h incubation, approx. 97 % of intact [68Ga]NOTA-GSA was
found compared with approx. 39 % for [68Ga]DTPA-GSA
(see Fig. 2).
Comment
Due to the physiological role of the asialoglycoprotein
receptor, which transfers the glycoproteins into liver cells
where they are degraded stability analysis in the liver would
not supply evaluable information about the stability of the
chelating systems and were thus not included.
Imaging and Biodistribution Data
Both tracers showed comparable uptake patterns, i.e., a
very fast accumulation throughout the entire liver with low
background activity in all other organs and a very fast
blood clearance (Fig. 3). In direct comparison,
[68Ga]DTPA-GSA reached a slightly higher liver uptake
level, but also showed a slow decrease over time (Fig. 3a).
Mean TACs generated at the left ventricle were very
similar, showing a very fast decrease to baseline in the first
5 min with [68Ga]NOTA-GSA reaching a lower final level
(Fig. 3c). The biodistribution confirmed the in vivo results,
showing only relevant uptake in liver tissue, while all other
organs remained below 0.5 % ID/g tissue (Fig. 4a). In-
depth analysis of the TACs, based on exponential fits, also
showed comparable results for most of the investigated
parameters. Overall fit-quality was excellent (R2 for liver
TAC is 0.99 ± 0.01 and for blood TAC 0.94 ± 0.03
averaged over all animals). Most parameters were compa-
rable (Table 1). The only significant difference was found
in the T90 value, where [
68Ga]NOTA-GSA showed slower
Fig. 4. Comparison of [68Ga]NOTA-GSA and [68Ga]DTPA-GSA ex vivo. In vivo imaging results were verified by biodistribution
studies, which were performed approximately 35 min after the PET emission scan, leading to a further reduction of liver uptake
in the [68Ga]DTPA-GSA group. a Again, both tracers showed high accumulation in the liver with only minor activity in all other
investigated organs. b Analysis of time activity curves revealed increased T90 times for [
68Ga]NOTA-GSA; however, all other
calculated parameters were identical.
Table 1. Characteristic parameters for blood clearance (T50 = time to reach 50 % of the maximum heart uptake, HH15 = blood activity at 15 min divided by
the blood activity at 3 min, and decaying constant b of the fit) and functional liver reserve (T90 = time to reach 90 % of the maximum liver uptake and LHL15
= liver activity at 15 min divided by the sum of liver and blood activity at 15 min). Data are given as mean ± standard deviation
Compound T50 [s] T90 [s] Clearance b HH15 LHL15
[68Ga]NOTA-GSA 42 ± 7 123 ± 10 1.39 ± 0.33 0.90 ± 0.05 0.92 ± 0.01
[68Ga]DTPA-GSA 46 ± 12 89 ± 3 1.47 ± 0.30 0.94 ± 0.06 0.90 ± 0.02
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uptake in comparison with [68Ga]DTPA-GSA (123 ± 10
vs. 89 ± 3 s, p G 0.01).
Discussion
[99mTc]GSA and dynamic SPECT including data analysis
using corresponding kinetic models [19] has successfully
been demonstrated to be able to determine non-invasively
regional hepatic function in a great number of patients
especially in Japan [14]. Recently, we introduced the Ga-68-
labeled analog [68Ga]DTPA-GSA and showed that the
technetium kit formulation can directly be labeled with Ga-
68 [17]. Moreover, the new tracer showed comparable liver
uptake as found for the 99mTc-analog. However, the stability
in human serum was inferior to [99mTc]GSA. This might be
due to the use of DTPA as gallium chelating system. In this
study, we replaced the DTPA moiety by a NOTA derivative
and could demonstrate that this modification resulted in a
much more stable GSA derivative ready for imaging liver
function in clinical settings.
Initially, DTPA-GSA was designed to be labeled with Tc-
99 m [20], for which DTPA is a well-established chelator. It
is known that DTPA possesses also a high complex stability
constant for Ga(III) [21]. Thus, it could be assumed that the
corresponding [68Ga]DTPA-GSA complexes should be
sufficiently stable for non-invasive imaging of the hepatic
function. However, in our previous study, we found
significant degradation in human serum within 30 min
[17]. The low stability of 68Ga-DTPA complexes is
confirmed by Anderson and Strand [22] who studied the
stability of a Ga-67-labeled monoclonal antibody and found
also low stability of the complex. To improve the metabolic
stability of the tracer, we replaced the DTPA moiety by a
NOTA derivative. It is known that the nine-membered ring
structure of NOTA forms a cage with an optimal size for
complexing Ga(III), resulting in a very high complex
stability constant [21].
Synthesis was carried out to produce the labeling
precursor with a similar average amount of chelating
moieties as found for the DTPA-GSA. Subsequent labeling
of NOTA-GSA was straightforward. Within 15 min at room
temperature, [68Ga]NOTA-GSA can be produced in high
radiochemical purity and yield. No subsequent purification
is required. However, it has to be mentioned that fixing of
the product, independent if NOTA-GSA or DTPA-GSA is
used, on a C-18 cartridge is not possible. Thus, it is
recommended to use a pre-purification procedure for
labeling to guarantee that no germanium breakthrough can
reach any patient preparation in a clinical setting.
Corresponding stability assays carried out either in
human or in rat serum both clearly demonstrated the desired
improvement. [68Ga]NOTA-GSA showed almost no release
of the radiometal over the observation period of 2 h in
human serum. Even the clinically established [99mTc]DTPA-
GSA revealed, over the whole observation period, more
degradation as found for [68Ga]NOTA-GSA [17]. However,
the imaging studies comparing the activity distribution and
pharmacokinetics of both 68Ga-labeled compounds reveal, at
first glance, only small differences in tracer uptake in the
liver and in the elimination of the tracer from the body.
Anyway, a more detailed analysis revealed that for
[68Ga]NOTA-GSA activity concentration in most organs
beside the liver is even lower as the already low values
found for [68Ga]DTPA-GSA (e.g., activity concentration in
blood for [68Ga]NOTA-GSA is less than half of the
concentration found for [68Ga]DTPA-GSA). Additionally,
TACs show a decrease in the liver uptake of [68Ga]DTPA-
GSA at later time points, whereas it remains constant for
[68Ga]NOTA-GSA. All this might be attributed to the lower
stability of [68Ga]DTPA-GSA. However, determination of
the relevant parameter based on the TACs resulted in
comparable values. An exception is the T90 value. Due to
the fact that the initial uptake of [68Ga]DTPA-GSA is faster
and also slightly higher than found for 68Ga-NOTA-GSA,
this value is smaller for [68Ga]DTPA-GSA. It seems that the
higher stability due to the introduced NOTA system reduces
the activity concentration in blood and may slow down the
tracer kinetics. As the T90 time may be more sensitive to
physiological parameters such as, e.g., blood flow, general
cardiac output, or depth of anesthesia, a relevant influence
on the determination of the hepatic function is not expected
based on this slight difference, especially since the LHL15
values are almost the same. Therefore, if using the entire
dataset to calculate functional liver reserve (LHL15) and
blood clearance (HH15), both tracers yield identical results.
Thus, the difference in metabolic stability does not signif-
icantly affect the final outcome. As the parameters LHL15
and HH15 were developed in a clinical setting using SPECT
imaging [23], they may not be the best suitable parameters to
characterize the fast metabolism of rats or mice. A recent
study by Schnabl et al. investigated the functional liver
reserve in an animal model of liver disease using T90 values
to characterize [68Ga]DTPA-GSA uptake [24]. Here, we see
small differences in the absolute values; however, their
influence on the sensitivity has to be investigated in studies
with corresponding disease models.
Conclusion
[68Ga]NOTA-GSA can be easily produced in high radio-
chemical purity and yield within 15-min reaction time. The
introduction of the NOTA moiety resulted in a significant
increase of the metabolic stability and in most organs in
lower background activity. However, comparison of LHL15
and HH15 indicates that the increased stability did not
further improve the diagnostic value. Thus, [68Ga]NOTA-
GSA and [68Ga]DTPA-GSA can be used as an equivalent
for imaging hepatic function with PET.
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